ARX NYSE Week ended 24 Jul 2026

Weekly Investor Report

Accelerant Holdings · Financial Services · Insurance Brokers

Open interactive chart View report data Download investor PDF
Latest close 14.23 USD
5.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 6.3% above the Trend Line and sits at 23.7% of its 52-week range. The latest completed week returned 5.3%, after a 4.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 60/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 28d.

Setup score 29 out of 100
Latest Close 14.23 USD 24 Jul 2026
1W Return 5.3% latest completed week
4W Return 4.9% short-term follow-through
12W Return 10.1% quarterly tape
Trend Breadth 1.9% 1 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 32.65% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 5.3% Latest completed week; four-week move 4.9%. Indicator stack 5/46 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 32.65% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 60/100 conviction; expected move 16.3%. News sentiment 54/100 64 relevant articles in the latest sentiment read. Event risk 28d Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 6.3% above the Trend Line and sits at 23.7% of its 52-week range. The latest completed week returned 5.3%, after a 4.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2712-week average 0.25

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.9% over four weeks, 10.1% over 12 weeks, and -51.8% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W5.3%
4W4.9%
12W10.1%
26W-3.4%
52W-51.8%
Active trend streak1 weeks
Active weeks in one year1
Trend breadth1.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.14Latest activity-pressure read.
Pressure change-81.5%Four-week change in activity pressure.
Leadership-13.25Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength26/100Blend of value, momentum, and quality. Underlying universe rank 75; rank 1 is best.
Value34/100Relative valuation strength. Underlying universe rank 67; rank 1 is best.
Quality82/100Profitability and accounting quality. Underlying universe rank 19; rank 1 is best.
Momentum5/100Medium-term price momentum. Underlying universe rank 96; rank 1 is best.
Growth86/100Revenue and earnings growth. Underlying universe rank 15; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
22.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
65.8%
Gross profit retained from each unit of revenue.
Operating margin
-144.2%
Operating profit retained from revenue.
Free-cash-flow margin
42.6%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
42.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-50.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-7.0%
Net share repurchases relative to market value.
Shareholder yield
-7.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ARX shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 16.3%, and Sharemaestro trend signal active.

Conviction60/100
Expected move16.3%
Put/call volume0.00
Pressure100
Speculation37
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 64 relevant articles.

18 positive · 41 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings28dNext report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
Options expected move16.3%Nearest-chain priced movement where available.
52-week drawdown-53.6%Distance below the 52-week high.
13-week volatility8.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+20.9%Week of 20 Mar.
Worst week-14.2%Week of 6 Feb.
Latest week+5.3%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses3
Sharp losses11
Recent vol8.1%13-week weekly-return volatility.
Base vol9.0%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -7.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis36/100

Latest 12-week confirmation: trend 1/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.27; No reversal markers Next-Week ExpectancyNegative 32.65%

Next-week expectancy is negative with a 32.65% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 84; Small Cap Core rank 80 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options38/100

ARX shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 16.3%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 16.3% Sentiment54/100

Weighted news tone is neutral across 64 relevant articles.

Accelerant (NYSE:ARX) Insider Francis James Oneill Sells 110,467 Shares Insiders50/100

No recent insider transaction evidence is stored.

 Earnings28d

Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202614.23 USD5.3%13.39 USD15.33 USD0.14-13.255.8MOn
17 Jul 202613.52 USD7.0%13.46 USD15.35 USD0.35-19.986.0MOff
10 Jul 202612.64 USD-8.2%13.55 USD15.39 USD0.50-11.4MOff
3 Jul 202613.77 USD1.5%13.64 USD15.45 USD0.65-7.1MOff
26 Jun 202613.57 USD5.8%13.69 USD15.48 USD0.77-19.6MOff
19 Jun 202612.83 USD-0.3%13.72 USD15.52 USD0.84-6.9MOff
12 Jun 202612.87 USD-13.1%13.72 USD15.58 USD1.00-7.5MOff
5 Jun 202614.80 USD-6.0%13.74 USD15.64 USD1.11-5.6MOff
29 May 202615.75 USD-7.5%13.66 USD15.65 USD1.12-7.0MOff
22 May 202617.04 USD11.7%13.52 USD15.65 USD1.01-7.6MOff
15 May 202615.25 USD17.0%13.37 USD15.62 USD0.90-9.2MOff
8 May 202613.04 USD0.8%13.28 USD15.63 USD0.81-5.1MOff
1 May 202612.93 USD-1.5%13.31 USD15.69 USD0.61-5.2MOff
24 Apr 202613.13 USD-6.8%13.37 USD15.76 USD0.48-6.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.